Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Huiyong Zhao

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Scientific Reports|November 19, 2021
Numerical study on a rotational hydraulic damper with variable damping coefficientHuiyong Zhao, Baohua Wang, Genfu Chen
Clinics and Research in Hepatology and Gastroenterology|April 30, 2021
The role of miRNA125b in the progression of hepatocellular carcinomaMinghao Yang, Sheng Wei, Huiyong Zhao, et al.
Scientific Reports|September 16, 2017
Iron deposition is associated with differential macrophage infiltration and therapeutic response to iron chelation in prostate cancerAvigdor Leftin, Huiyong Zhao, Mesru Turkekul, et al.
Neoplasia (New York, N.Y.)|April 14, 2023
Hepatocellular carcinoma-derived FOXO1 inhibits tumor progression by suppressing IL-6 secretion from macrophagesXiao Cui, Huiyong Zhao, Sheng Wei, et al.
Cell Death Discovery|April 10, 2023
Blocking the CXCL1-CXCR2 axis enhances the effects of doxorubicin in HCC by remodelling the tumour microenvironment via the NF-κB/IL-1β/CXCL1 signalling pathwayHuiyong Zhao, Sheng Wei, Dachen Zhou, et al.
Cell Reports|October 23, 2021
Loss of FBXO31-mediated degradation of DUSP6 dysregulates ERK and PI3K-AKT signaling and promotes prostate tumorigenesisShanshan Duan, Loredana Moro, Rui Qu, et al.
Molecular Therapy Oncolytics|April 30, 2020
Stomatin-like Protein 2 Promotes Tumor Cell Survival by Activating the JAK2-STAT3-PIM1 Pathway, Suggesting a Novel Therapy in CRCQiang Liu, Anqi Li, Lisha Wang, et al.
Molecular Cancer Therapeutics|November 18, 2021
Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor ActivityYiyu Dong, Yongxing Gong, Fengshen Kuo, et al.
Nature|February 11, 2016
Deriving human ENS lineages for cell therapy and drug discovery in Hirschsprung diseaseFaranak Fattahi, Julius A Steinbeck, Sonja Kriks, et al.
The Oncologist|August 24, 2023
Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced CancersNaryan Rustgi, Ann Maria, Nicolas Toumbacaris, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Scientific Reports|November 19, 2021
Numerical study on a rotational hydraulic damper with variable damping coefficientHuiyong Zhao, Baohua Wang, Genfu Chen
Clinics and Research in Hepatology and Gastroenterology|April 30, 2021
The role of miRNA125b in the progression of hepatocellular carcinomaMinghao Yang, Sheng Wei, Huiyong Zhao, et al.
Scientific Reports|September 16, 2017
Iron deposition is associated with differential macrophage infiltration and therapeutic response to iron chelation in prostate cancerAvigdor Leftin, Huiyong Zhao, Mesru Turkekul, et al.
Neoplasia (New York, N.Y.)|April 14, 2023
Hepatocellular carcinoma-derived FOXO1 inhibits tumor progression by suppressing IL-6 secretion from macrophagesXiao Cui, Huiyong Zhao, Sheng Wei, et al.
Cell Death Discovery|April 10, 2023
Blocking the CXCL1-CXCR2 axis enhances the effects of doxorubicin in HCC by remodelling the tumour microenvironment via the NF-κB/IL-1β/CXCL1 signalling pathwayHuiyong Zhao, Sheng Wei, Dachen Zhou, et al.
Cell Reports|October 23, 2021
Loss of FBXO31-mediated degradation of DUSP6 dysregulates ERK and PI3K-AKT signaling and promotes prostate tumorigenesisShanshan Duan, Loredana Moro, Rui Qu, et al.
Molecular Therapy Oncolytics|April 30, 2020
Stomatin-like Protein 2 Promotes Tumor Cell Survival by Activating the JAK2-STAT3-PIM1 Pathway, Suggesting a Novel Therapy in CRCQiang Liu, Anqi Li, Lisha Wang, et al.
Molecular Cancer Therapeutics|November 18, 2021
Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor ActivityYiyu Dong, Yongxing Gong, Fengshen Kuo, et al.
Nature|February 11, 2016
Deriving human ENS lineages for cell therapy and drug discovery in Hirschsprung diseaseFaranak Fattahi, Julius A Steinbeck, Sonja Kriks, et al.
The Oncologist|August 24, 2023
Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced CancersNaryan Rustgi, Ann Maria, Nicolas Toumbacaris, et al.
Pageof 4